Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors

The contribution of bone marrow-derived circulating endothelial progenitor cells (CEPs) to tumor angiogenesis has been controversial, primarily because of their low numbers in blood vessels of untreated tumors. We show that treatment of tumor-bearing mice with vascular disrupting agents (VDAs) leads...

Full description

Saved in:
Bibliographic Details
Published in:Science (American Association for the Advancement of Science) 2006-09, Vol.313 (5794), p.1785-1787
Main Authors: Shaked, Yuval, Ciarrocchi, Alessia, Franco, Marcela, Lee, Christina R, Man, Shan, Cheung, Alison M, Hicklin, Daniel J, Chaplin, David, Foster, F. Stuart, Benezra, Robert, Kerbel, Robert S
Format: Article
Language:English
Subjects:
Angiogenesis inhibitors
Angiogenesis Inhibitors - therapeutic use
Animal tumors. Experimental tumors
Animals
Antibodies, Monoclonal - therapeutic use
Antineoplastic Agents, Phytogenic - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Antineoplastics
Biological and medical sciences
Blood vessels
Bone marrow
Bone marrow cells
Bone Marrow Cells - cytology
Bone Marrow Cells - physiology
Bones
Cell Hypoxia
Cell Line, Tumor
Cells
Diphosphates - therapeutic use
Dosage
Drug therapy
Endothelial Cells - cytology
Experimental tumors, general aspects
Humans
Hypoxia
Medical sciences
Mice
Mice, Inbred C57BL
Mice, Nude
Necrosis
Neoplasm Transplantation
Neoplasms, Experimental - blood supply
Neoplasms, Experimental - drug therapy
Neoplasms, Experimental - pathology
Neovascularization, Pathologic
Stem Cells - physiology
Stilbenes - therapeutic use
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The contribution of bone marrow-derived circulating endothelial progenitor cells (CEPs) to tumor angiogenesis has been controversial, primarily because of their low numbers in blood vessels of untreated tumors. We show that treatment of tumor-bearing mice with vascular disrupting agents (VDAs) leads to an acute mobilization of CEPs, which home to the viable tumor rim that characteristically remains after such therapy. Disruption of this CEP spike by antiangiogenic drugs or by genetic manipulation resulted in marked reductions in tumor rim size and blood flow as well as enhanced VDA antitumor activity. These findings also provide a mechanistic rationale for the enhanced efficacy of VDAs when combined with antiangiogenic drugs.
ISSN:0036-8075
1095-9203
DOI:10.1126/science.1127592